The biological products sector maintains rapid growth, and the prosperity of these fields is high

With the disclosure of the three quarterly reports, the performance of each segment of the medicine has also surfaced
.
Among them, the biological products segment maintained rapid growth in the first three quarters of 2021.
A total of 9 pharmaceutical companies increased their net profit in the first three quarters by more than 1,000% year-on-year, including Rejing Bio, Oriental Bio, Yan'an Bikang, Laimei Pharmaceutical, Northeast Pharmaceutical and so on
.
Among them, Hotview Biopharmaceuticals issued a third-quarter results announcement on the evening of October 29, stating that the company achieved operating income of approximately 196 million yuan in the third quarter, a year-on-year increase of 252.
17%
.
The net profit attributable to shareholders of listed companies was approximately 23.
72 million yuan, a year-on-year increase of 660.
26%
.
A review found that the substantial increase in the operating performance of Hotview Bio in the first three quarters was mainly related to the improvement of the focus on promoting the marketization of testing products this year, as well as the active expansion of the international market, and the surge in foreign trade orders
.
Oriental Bio released its third quarter report on the evening of October 29.
From the beginning of the year to the end of the reporting period, it achieved operating income of 7.
4 billion yuan, a year-on-year increase of 572.
38%
.
The net profit attributable to shareholders of listed companies was 3.
919 billion yuan, a year-on-year increase of 489.
85%
.
The performance growth in the first three quarters was mainly due to the significant year-on-year increase in sales revenue of related testing reagents from the beginning of the year to the end of the reporting period
.
Yan'an Bikang released the first three quarters of 2021 performance report on October 28
.
In the first nine months, the company achieved operating income of 5.
591 billion yuan, a year-on-year increase of 8.
80%, and net profit of 609 million yuan, a year-on-year increase of 4672.
62%
.
The main reason for the company's soaring performance is the increase in the price of lithium hexafluorophosphate
.
In addition, the 2021 third quarter report of Laimei Pharmaceuticals showed that the company's main operating income was 892 million yuan, a year-on-year decrease of 16.
79%; the net profit attributable to the parent was 19,969,200 yuan, a year-on-year increase of 3565.
17%
.
Northeast Pharmaceutical's 2021 third quarter report shows that the company’s main operating income was 6.
105 billion yuan, an increase of 11.
27% year-on-year; net profit attributable to the parent was 25,497,600 yuan, an increase of 300.
49% year-on-year; non-net profit was 9,329,200 yuan, an increase of 184.
1% year-on-year
.
On the whole, the industry believes that the biological products sector has achieved high growth, among which the vaccine, growth hormone and other sub-sectors have high prosperity and have great growth potential
.
Especially in the field of vaccines, in the first three quarters, vaccine giant Cansino achieved a net profit of 1.
334 billion yuan, turning losses into profits year-on-year
.
For the reason for the significant increase in performance, the company attributed to the fact that the recombinant new coronavirus vaccine (type 5 adenovirus vector) has obtained emergency use authorization from Mexico, Pakistan and other countries and the conditional listing approval in China, which has a positive impact on operating income
.
Zhifei Biotechnology still maintained high growth in the first three quarters of this year: operating income in the first three quarters was 21.
829 billion yuan, a year-on-year increase of 97.
55%; net profit attributable to shareholders of listed companies was 8.
404 billion yuan, a year-on-year increase of 239.
05%
.
Regarding the increase in operating income, Zhifei Biological explained that it was mainly due to the increase in sales of independent products in this period
.
In addition, Kangtai Biological also achieved strong performance growth
.
The net profit attributable to the parent in the first three quarters was 1.
036 billion yuan, a year-on-year increase of 139.
13%, of which the net profit attributable to the parent in the third quarter was 700 million yuan, a year-on-year increase of 303.
21%
.
It is reported that the large increase in performance in the third quarter was mainly due to the increase in the contribution of the new crown vaccine and the resumption of production and sales of the hepatitis B vaccine
.
Based on the original forecast that the market size will reach 44.
8 billion U.
S.
dollars in 2024, evaluatePharma puts forward a new forecast for the global vaccine market.
By 2026, the global vaccine market will reach 56.
1 billion U.
S.
dollars
.
At present, China's vaccine industry has entered a new stage of development, with huge room for development
.